ClinicalTrials.gg
CompletedNCT01115491Updated Dec 8, 2014Results posted

A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme

A Phase 2 interventional study of bevacizumab [Avastin] and temozolomide in Glioblastoma Multiforme, sponsored by Hoffmann-La Roche. Completed at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-08.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
128th of 221
32 · median 41
Started
2010
with 10 others
Phase 2
99 of 232
13 open now
Registered
105th of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 128th largest by enrollment of the 221 interventional ones that give a count, is one of 11 that started in 2010, is one of 99 in phase 2, and was the 105th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment failure. Patients will receive bevacizumab 10 mg/kg intravenously every two weeks until disease progression, consent withdrawal, or unacceptable toxicity. Anticipated time on study treatment is 12-24 months.

03

Conditions studied

  • Glioblastoma Multiforme

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Histological diagnosis of glioblastoma multiforme (GBM) documented by surgical resection or .
  • They should be patients in a first relapse treated with radiotherapy and chemotherapy and chemotherapy based on temozolomide 150-200 mg/m2 on days 1 to 5 every 28 days (Stupp regimen) for at least three cycles. At least 4 weeks must have lapsed since previous chemotherapy and 3 months since the last dose of radiotherapy.
  • Use of an effective method by patients and their partners.
  • Stable or decreasing dose for the five days prior to study entry
  • Adequate hematological function
  • Adequate liver function
  • Adequate kidney function

Exclusion criteria

Exclusion Criteria:

  • Signs of recent bleeding at the MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving bleeding changes related to surgery, and presence of punctate hemorrhage in the tumor will be allowed to participate in the study.
  • Prior treatment with bevacizumab
  • Poorly controlled arterial hypertension
  • History of hypertensive crises or hypertensive encephalopathy
  • New York Health Association () Class II or higher congestive heart failure
  • History of myocardial infarction or unstable angina pectoris within six months of study entry
  • History of stroke or within six months of study entry
  • Significant vascular disease within six months of study entry
  • History of hemoptysis > grade 2 according to the NCI CTC criteria within one month of study entry
  • Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
  • Major surgery, open , intracranial biopsy, ventriculoperitoneal shunt, or major traumatic lesion within 28 days of study entry.
  • Core needle biopsy (excluding intracranial biopsy) or other minor surgery within seven days of randomization. Placement of a central vascular access device (CVAD) if performed in the two days prior to bevacizumab administration
  • History of abdominal fistula or gastrointestinal perforation within six months of study entry
  • History of intracranial abscess within six months of randomization
  • Any prior malignant neoplasm treated with curative intent in the five years prior to study entry, except for adequately controlled limited basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
  • Patients with any other metabolic or psychological disease
  • to products derived from Chinese hamster ovary cells or to other humanized or recombinant human antibodies
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    A

    Drug: bevacizumab [Avastin] · Drug: temozolomide

Interventions

  • Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks

  • Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) - Percentage of Participants With an Event

    PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment.

    Time frame: Baseline (BL), every 28 days, until progression, death or end-of-study, an average of 32 weeks

  2. PFS - Time to Event

    PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment. PFS was estimated using the Kaplan-Meier method.

    Time frame: BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks

  3. PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study

    Time frame: BL, 24 weeks (after 6th cycle)

Secondary outcomes

  1. Overall Survival - Percentage of Participants With an Event

    Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact.

    Time frame: BL, every 28 days, until death or end-of-study, an average of 32 weeks

  2. Overall Survival - Time to Event

    Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact. Median overall survival was estimated using the Kaplan-Meier method.

    Time frame: BL, every 28 days, until death or end-of-study, an average of 32 weeks

  3. Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)

    Overall response was defined as the percentage of participants who obtained CR or PR using adapted MacDonald criteria. CR: disappearance of all index and non-index lesions, confirmed no less than 4 weeks after assessment, no evidence of disease progression; corticosteroid dosage at or below 20 mg hydrocortisone daily; no neurological changes or an improvement as compared to last disease assessment. PR was defined as: Fifty percent or greater decrease in the sum of products of the larger diameter and the larger perpendicular diameter of all index lesions confirmed no less than 4 weeks after assessment, no evidence of disease progression and the absence of progressive, or non-evaluable disease status for non-index legions; unchanged, or decreased corticosteroid dose as compared to the last disease assessment; no neurological changes or an improvement as compared to the neurological examination at last disease assessment.

    Time frame: BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks

07

Results

Posted Dec 8, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Temozolomide
Started32
Completed2
Not completed30
Withdrew: Death22
Withdrew: Adverse event3
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1

Outcome measures

PrimaryProgression-Free Survival (PFS) - Percentage of Participants With an Event

PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment.

Time frame:
Baseline (BL), every 28 days, until progression, death or end-of-study, an average of 32 weeks
Reported as:
Number · percentage of participants
Progression-Free Survival (PFS) - Percentage of Participants With an Event
percentage of participantsBevacizumab + Temozolomide
Progression-Free Survival (PFS) - Percentage of Participants With an Event96.88
PrimaryPFS - Time to Event

PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment. PFS was estimated using the Kaplan-Meier method.

Time frame:
BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks
Reported as:
Median · weeks
PFS - Time to Event
weeksBevacizumab + Temozolomide
PFS - Time to Event18.29 (15.43 to 23.57)
SecondaryOverall Survival - Percentage of Participants With an Event

Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact.

Time frame:
BL, every 28 days, until death or end-of-study, an average of 32 weeks
Reported as:
Number · percentage of participants
Overall Survival - Percentage of Participants With an Event
percentage of participantsBevacizumab + Temozolomide
Overall Survival - Percentage of Participants With an Event75.00
SecondaryOverall Survival - Time to Event

Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact. Median overall survival was estimated using the Kaplan-Meier method.

Time frame:
BL, every 28 days, until death or end-of-study, an average of 32 weeks
Reported as:
Median · weeks
Overall Survival - Time to Event
weeksBevacizumab + Temozolomide
Overall Survival - Time to Event31.43 (25.14 to 38.29)
PrimaryPFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study
Time frame:
BL, 24 weeks (after 6th cycle)
Reported as:
Number · survival probability
PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study
survival probabilityBevacizumab + Temozolomide
PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study0.30000 ± 0.0819
SecondaryPercentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)

Overall response was defined as the percentage of participants who obtained CR or PR using adapted MacDonald criteria. CR: disappearance of all index and non-index lesions, confirmed no less than 4 weeks after assessment, no evidence of disease progression; corticosteroid dosage at or below 20 mg hydrocortisone daily; no neurological changes or an improvement as compared to last disease assessment. PR was defined as: Fifty percent or greater decrease in the sum of products of the larger diameter and the larger perpendicular diameter of all index lesions confirmed no less than 4 weeks after assessment, no evidence of disease progression and the absence of progressive, or non-evaluable disease status for non-index legions; unchanged, or decreased corticosteroid dose as compared to the last disease assessment; no neurological changes or an improvement as compared to the neurological examination at last disease assessment.

Time frame:
BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)
percentage of participantsBevacizumab + Temozolomide
Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)40.6

Adverse events

Collected over Adverse events (AEs) were collected from the date of start of study treatment to 90 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Temozolomide—8/32 (25%)32/32 (100%)
Most frequent serious events
Most frequent serious events
EventBevacizumab + Temozolomide
Lung (pneumonia)Infections and infestations2/32
FeverGeneral disorders2/32
Upper respiratory tract infectionInfections and infestations1/32
Neurological disorder NOSNervous system disorders1/32
SeizuresNervous system disorders1/32
ThrombosisVascular disorders1/32
Bladder haemorrhageRenal and urinary disorders1/32
Intracranial haemorrhageBlood and lymphatic system disorders1/32
Back painMusculoskeletal and connective tissue disorders1/32
Most frequent other events
Showing 10 of 43
Most frequent other events
EventBevacizumab + Temozolomide
FatigueGeneral disorders18/32
Lymphocyte count decreasedBlood and lymphatic system disorders16/32
Platelet count decreasedBlood and lymphatic system disorders15/32
NauseaGastrointestinal disorders11/32
Olfactory nerve disorderNervous system disorders9/32
HeadacheNervous system disorders9/32
AnorexiaMetabolism and nutrition disorders8/32
Upper respiratory infectionInfections and infestations8/32
HypertensionVascular disorders7/32
Neutrophil count decreasedBlood and lymphatic system disorders6/32

Baseline characteristics

Intent-to-treat (ITT) population: all enrolled participants.

Age, Continuous
Age, Continuous(years)Bevacizumab + Temozolomide
Mean56.19 ± 10.58
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Temozolomide
Female15
Male17
08

Study locations

8 sites
  • Barcelona, 08025, Spain
  • Barcelona, 08907, Spain
  • Barcelona, 08916, Spain
  • Madrid, 28040, Spain
  • Madrid, 28041, Spain
  • Madrid, 28046, Spain
  • Valencia, 41014, Spain
  • Valencia, 46026, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2010
First posted
May 4, 2010
Start
Jun 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Dec 8, 2014
Last update
Dec 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01115491
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 4, 2010
Start date
Jun 2010
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Dec 8, 2014
Last update
Dec 8, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion